Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Veliparib with Chemotherapy in NSCLC
NCT02944396Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of veliparib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Progression-free survival at 3.5 years and Recommended Phase 2 dose at 6 weeks. Started Dec 2016; status: completed.
02
Drugs
veliparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02944396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944396.